Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akorn, Inc. stock logo
AKRX
Akorn
$0.19
$0.09
$5.46
$3.60M0.959.60 million shs1.19 million shs
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
$0.22
$0.22
$0.17
$0.40
$6.47M0.527,946 shsN/A
NSPX
Inspyr Therapeutics
$0.00
$0.00
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
$2.06
$1.26
$4.26
$8.11M0.98162,968 shs2,579 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$0.16
+6.8%
$0.15
$0.12
$1.52
$2.34M1.28805,015 shs91,994 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akorn, Inc. stock logo
AKRX
Akorn
0.00%0.00%0.00%0.00%0.00%
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
0.00%0.00%-6.36%-12.96%-40.61%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+4.93%-2.48%+11.63%-7.95%-84.42%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/AN/AN/AN/AN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
2.2279 of 5 stars
3.55.00.00.00.60.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.00
Buy$3.251,964.80% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akorn, Inc. stock logo
AKRX
Akorn
$682.43M0.00N/A0.19$1.86 per share0.00
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
$50.67M0.13$0.04 per share5.75$0.63 per share0.34
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/A$2.48 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.27M0.19N/AN/A$1.72 per share0.09

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akorn, Inc. stock logo
AKRX
Akorn
-$226.77M-$0.34N/AN/AN/A-55.64%8.53%1.31%N/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
-$30K-$0.01N/AN/A-0.76%-2.05%-1.47%5/6/2024 (Estimated)
NSPX
Inspyr Therapeutics
-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
-$8.64MN/A0.00N/AN/AN/A-72.60%-55.68%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$5.15M-$0.97N/AN/AN/A-41.24%-58.93%-26.92%6/19/2024 (Estimated)

Latest AKRX, SNOA, REXN, NSPX, and INBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/12/2024Q2 2024
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/A-$0.01-$0.01-$0.01N/A$11.51 million
2/8/202412/31/2023
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.21-$0.06+$0.15-$0.04N/A$3.14 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/AN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akorn, Inc. stock logo
AKRX
Akorn
0.09
0.50
0.32
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/A
2.93
0.84
NSPX
Inspyr Therapeutics
N/A
0.09
0.09
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/A
3.37
3.37
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
4.07
3.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akorn, Inc. stock logo
AKRX
Akorn
64.03%
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
25.25%
NSPX
Inspyr Therapeutics
0.02%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
7.49%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akorn, Inc. stock logo
AKRX
Akorn
2,227133.15 millionN/AOptionable
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
14130.10 million16.37 millionNot Optionable
NSPX
Inspyr Therapeutics
1543.15 millionN/ANot Optionable
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
54.48 millionN/AOptionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
915.61 million14.17 millionNot Optionable

AKRX, SNOA, REXN, NSPX, and INBP Headlines

SourceHeadline
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
finanznachrichten.de - April 9 at 10:39 AM
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesSonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
accesswire.com - April 9 at 7:30 AM
Sonoma Pharmaceuticals Reports Recent Publication…Sonoma Pharmaceuticals Reports Recent Publication…
pharmiweb.com - April 4 at 10:28 AM
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract InfectionsSonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
accesswire.com - April 4 at 7:30 AM
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
finanznachrichten.de - March 28 at 9:52 PM
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesSonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
accesswire.com - March 28 at 4:01 PM
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other TopicalsSonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
accesswire.com - March 27 at 7:30 AM
Sonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagSonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - February 10 at 2:56 PM
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
finance.yahoo.com - February 8 at 4:32 PM
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily UseSonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
finance.yahoo.com - January 23 at 9:51 AM
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
finanznachrichten.de - November 13 at 5:52 PM
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
finance.yahoo.com - November 13 at 5:52 PM
Sonoma Pharmaceuticals Inc SNOASonoma Pharmaceuticals Inc SNOA
morningstar.com - November 11 at 10:31 PM
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall ConferenceSonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference
finance.yahoo.com - November 3 at 8:49 AM
US Stocks Mixed; Bristol Myers Posts Upbeat EarningsUS Stocks Mixed; Bristol Myers Posts Upbeat Earnings
benzinga.com - October 26 at 6:54 PM
Crude Oil Down 2.5%; Mastercard Posts Upbeat EarningsCrude Oil Down 2.5%; Mastercard Posts Upbeat Earnings
markets.businessinsider.com - October 26 at 6:54 PM
Dow Dips Over 100 Points; US GDP Growth Tops ExpectationsDow Dips Over 100 Points; US GDP Growth Tops Expectations
benzinga.com - October 26 at 1:54 PM
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common StockSonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock
finance.yahoo.com - October 26 at 1:54 PM
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62%U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62%
msn.com - October 24 at 10:20 PM
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.62%U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.62%
msn.com - October 24 at 5:19 PM
macOS Sonoma now available: Heres whats newmacOS Sonoma now available: Here's what's new
pocketnow.com - September 29 at 3:54 PM
macOS SonomamacOS Sonoma
macrumors.com - September 28 at 12:39 PM
Apple macOS Sonoma system requirements – can macOS 14 run on your Mac?Apple macOS Sonoma system requirements – can macOS 14 run on your Mac?
stuff.tv - September 14 at 7:13 AM
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn AdvancedNational Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
finance.yahoo.com - August 15 at 10:23 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akorn logo

Akorn

NASDAQ:AKRX
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Integrated BioPharma logo

Integrated BioPharma

OTCMKTS:INBP
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Inspyr Therapeutics

OTCMKTS:NSPX
Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.
Rexahn Pharmaceuticals logo

Rexahn Pharmaceuticals

NASDAQ:REXN
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Sonoma Pharmaceuticals logo

Sonoma Pharmaceuticals

NASDAQ:SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.